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Activity of liver x receptor (LXR), the homeostatic regulator of cholesterol meta-
bolism, is elevated in triple-negative breast cancer (BCa) relative to other BCa
subtypes, driving drug resistance andmetastatic gene signatures. The loci encod-
ing LXRa and LXRb produce multiple alternatively spliced proteins, but the true
range of variants and their relevance to cancer remain poorly defined. Here, we
report seven LXR splice variants, three of which have not previously been re-
ported and five that were prognostic for disease-free survival. Expression of
full-length LXRa splice variants was associated with poor prognosis, consistent
with a role as an oncogenic driver of triple-negative tumor pathophysiology. Con-
trary to this was the observation that high expression of truncated LXRa splice
variants or any LXRb splice variant was associated with longer survival. These
findings indicate that LXR isoform abundance is an important aspect of under-
standing the link between dysregulated cholesterol metabolism and cancer path-
ophysiology.
INTRODUCTION
Breast cancer (BCa) is the most commonly diagnosed cancer in women in the UK and is the cause of
600,000 cancer death worldwide (Bray et al., 2018). The triple-negative BCa (TNBC) subtype has higher
rates of recurrence in the first three years after prognosis and increased mortality rates (Hudis and Gianni,
2011). TNBC is defined by low estrogen (ER), progesterone (PR), and Her2 receptor expression (Perou et al.,
2000). Due to this lack of expression of therapeutic molecular targets, primary disease can only be system-
ically treated with cytotoxic chemotherapy, and TNBC remains a cancer of unmet clinical need; novel tar-
geted therapies are urgently needed.
Nutritional and epidemiological studies indicate that cholesterol metabolism may play a role in the etiol-
ogy and severity of TNBC (Cioccoloni et al., 2020; Jiang et al., 2019; Liu et al., 2017; WCRF/AICR, 2017). The
liver x receptors (LXRa/NR1H3; LXRb/NR1H2) are homeostatic regulators of cholesterol metabolism and as
such have been suggested as potential therapeutic targets. LXRa activation by hydroxylated cholesterol
(oxysterols) has been linked to poor survival by driving multi-drug resistance in patients with TNBC (Hutch-
inson et al., 2021) and increased metastasis in mouse models (Baek et al., 2017; Nelson et al., 2013). On the
other hand, LXRb activation by histamine conjugated oxysterols such as dendrogenin A can induce lethal
autophagy in BCa (Poirot and Silvente-Poirot, 2018). Intriguingly, ER-negative and ER-positive BCa sub-
types respond differently to LXR ligands (Hutchinson et al., 2019) even though oxysterol concentrations
are similar between BCa subtypes (Solheim et al., 2019). Collectively, these data imply that the differential
control over LXR’s transcriptional regulation between subtypes is not simply at the level of ligand type or
concentration.
LXRa and LXRb are each thought to be translated from their own single main transcript variants, producing
447 and 460 amino acid proteins, respectively (Shinar et al., 1994; Willy et al., 1995). These ‘‘full-length’’ iso-
forms harbor domains that provide distinct functions, including activation function 1 (AF1), hinge region
(H), DNA-binding domain (DBD), and ligand-binding domain (LBD) (Willy et al., 1995), as is typical for
many ligand-dependent nuclear receptors.
Aside from the canonical full-length LXRa1, four additional LXRa splice variants have been reported in hu-
man cell lines or tissue samples previously (Chen et al., 2005; Endo-Umeda et al., 2012), and a single report
found one alternative splice variant to the major LXRb1 isoform (Hashimoto et al., 2009). These studiesiScience 24, 103212, October 22, 2021 ª 2021 The Authors.
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Figure 1. Schematic diagram of LXR splice variants
(A and B) Schematic diagram of (A) LXRa and (B) LXRb splice variants detected at RNA and protein level in this study. AF1 =
activation function 1; DBD =DNAbinding domain; H = hinge; LBD = ligand binding domain. The numbers right below the




Articlefound that alternative splicing of LXR disrupts the integrity of the DNA- and ligand-binding domains,
rendering the proteins with reduced or even absent response to ligand (Chen et al., 2005; Endo-Umeda
et al., 2012). In the case of LXRb, a single known splice variant functions as an RNA co-activator (Hashimoto
et al., 2009). Genomic and proteomic databases including National Center for Biotechnology Information
(NCBI) (Pruitt et al., 2005), The Cancer Genome Atlas (TCGA) Splicing Variants database (TSVdb (Sun et al.,
2018)), Ensembl (Aken et al., 2016), and Universal Protein Resource (UniProt) (Bairoch et al., 2005) indicate
that the LXRa and LXRb genes encode more splice variants than previously reported. For example, a study
exploring some of these databases indicated up to 62 different LXRa transcript variants (Annalora et al.,
2020), making it the most extensively spliced member of the nuclear receptor superfamily.
However, experimental evidence for the existence of such an array of isoforms is lacking. Given the strong links
between cholesterol metabolism, for which the LXRs play vital regulatory roles, and TNBC etiology, the aim of
this study was to describe the LXR splice repertoire and clinical significance in human triple-negative BCa.
RESULTS
Database analysis of LXR transcript splice variance in breast cancer
To evaluate the variety of LXR splice variants, the NCBI and ENSEMBL databases were mined for mRNA
transcript variants and UNIPROT database for protein variants. In total, this analysis indicated there were
64 LXRa transcript variants, of which 48 could code for 26 LXRa protein variants (see Figure S1). We found
11 LXRb transcript variants that could code for 9 LXRb proteins (see Figure S2). These included all nine
variants (a1-a5, b1-b4) later observed in BCa cells and/or breast tumor tissue (summarized in Figure 1).
Previous publications have used a consistent naming system for the LXRa isoforms but deviate from
nomenclature of NCBI, TCGA Splicing (TSVdb), ENSEMBL, and UNIPROT databases. For example,
NM_001130101 previously referred to as a3 (Chen et al., 2005; Endo-Umeda et al., 2012; Rondanino
et al., 2014) is annotated as a2 in the NCBI database. NM_001130102 has previously been referred to as
a2 (Chen et al., 2005; Rondanino et al., 2014) but is annotated as a3 in the NCBI database. Furthermore,
due to the complexity of potential LXR transcript variants (Annalora et al., 2020), the naming system2 iScience 24, 103212, October 22, 2021
Figure 2. LXR splicing events in BCa validated by TCGA Splicing Variants database (TSVdb)
(A) Heatmap visualization of normalized RSEM (RNA-Seq by Expectation Maximization) value expression of LXRa and
LXRb in 1,103 TCGA BCa samples. Note: Transcript uc002prv was only reported in TSVdb and is not recorded in NCBI,
ENSEMBL, or UNIPROT databases.
(B) Comparison of LXR transcript variant expression, for a1.1, a1.2, a3.1, and b1.1, in matched tumor and normal tissues
grouped by BCa subtype, ER+ (n = 78), and TNBC (n = 18). Statistical analysis by Mann-Whitney two-tailed U tests. P %
0.05 was considered significant. The line shows the median value, the box shows 10th to 90th percentile, and whiskers
show minimum-to-maximum value.
(C and D) Kaplan-Meier survival curves plotting disease-free survival of patients with TCGA BCa. The TCGA BCa samples
(downloaded from TSvdb TCGA splicing database) were grouped by BCa subtype, (C) ER+ (n = 803), and (D) TNBC (n =
101). Survival curves of each subtype were separated into two groups: no event (ER+ = 675, TNBC = 79) and event (ER+ =
128; TNBC = 22) based on their overall survival data reported in cBioportal. p value is based on the log rank test, and data




Articlefrom previous publications (Chen et al., 2005; Endo-Umeda et al., 2012; Rondanino et al., 2014) was not
appropriate, and instead, the NCBI annotation systemwas adopted. Details of all previous reported primer
pairs used to detect LXR are available in Figure S3. Full details of how variants pertain to databases and
previous studies are provided for LXRa in Figure S4 and Table S1 and for LXRb in Figure S5 and Table
S2. During this annotation and documentation process, some NCBI predicted LXR isoforms were found
to be identical to curated isoforms. For example, the LXRax5 amino acid sequence is derived from two
NCBI predicted isoforms (XP_011518107.1 and XP_005252763.1) and is identical to the LXRa1 amino
acid sequence (NP_005684.2). We confirmed this using Clustal Omega multiple sequence alignment soft-
ware (https://www.ebi.ac.uk/Tools/msa/clustalo/) (EMBL-EBI, Dublin, Ireland) (Figure S6).
To investigate the expression of LXR splice variants in BCa, we first examined RNA-seq data from 1,103 BCa
tumors in the TCGA Pan-Cancer Atlas utilizing the TSVdb web interface (Sun et al., 2018). These data
showed that out of six LXRa and three LXRb splice variants with RSEM reads (Li and Dewey, 2011), the
a1.1 (median RSEM value = 231.52) and b1.1 (median RSEM value = 1158.53) variants were most highly ex-




Articlevalue = 31.88), and b2 (median RSEM value = 21.69) transcripts were expressed at low levels. No other tran-
script variants were detected in this database (Figure 2A).
We further examined expression of the four variants (a1.1, a1.2, a3.1, b1.1) in matched tumor and normal
samples from ER+ and TNBC subtypes. Both a1.1 and a1.2 were expressed at significantly higher levels
in ER+ and TNBC tumor tissue compared to adjacent normal tissue (p < 0.01 for all; Figure 2B). a3.1
expression was lower in ER+ tumor tissue than adjacent normal (p = 0.011; Figure 2B), but there was
no difference in expression of this isoform between tumor and normal tissue in TNBC disease. There
was no difference in b1.1 expression in either ER+ or TNBC tumors relative to adjacent normal (p >
0.05; Figure 2B). There was no difference in expression of any individual LXR variants between ER+
and TNBC tumors (see Figure S7).
We then examined if transcript variant expression identified in TSVdb was associated with disease-free sur-
vival (DFS) in ER+ (Figure 2C) or patients with TNBC (Figure 2D). High a1.2 expression was associated with
shorter DFS in ER+ patients (p = 0.029), while in patients with TNBC, high a1.1 expression was associated
with shorter DFS (p = 0.04). Neither a3.1 nor LXRb expression was associated with DFS. These data suggest
that elevated LXRa1 (a1) may be linked to poor prognosis in patients with BCa.LXR expression in breast cancer cell lines
Having established evidence for LXR splice variant expression in the TSVdb dataset, we next examined
transcript expression in a panel of BCa cell lines. HEPG2 cells express relatively high levels of both LXRa
and LXRb (Laffitte et al., 2001) so were included as a positive control. Total LXRa and LXRb RNA expression
was determined using SYBR green primers that target the exon 9–10 junction of LXRa and exon 8–9 junction
for LXRb. These exons are spliced together in all previously reported variants and in all variants described in
this study (see Tables S1 and S2; Figures S1 and S2) and were used to estimate the total pool of LXR tran-
scripts and for normalization of variant expression.
The claudin high TNBC cell line MDA.MB.468 had highest expression of LXRa of all BCa cell lines (p < 0.05).
MDA.MB.468, MDA.MB.453, and BT474 had highest LXRb (Figures 3A and 3B). In all cell lines analyzed, the
expression of LXRa mRNA was significantly lower than that of LXRb (all p < 0.05; Figure S8), recapitulating
the observations from the TSVdb (Figure 2A). Across the cell lines, the transcripts measured accounted for
between 91 and 100% of LXRa (exon 9–10) and 94–102% of LXRb (exon 8–9) exon-exon boundaries (Figures
3C and 3D), indicating other variants were expressed at very low levels or did not contain the exon 9–10/7–8
boundaries. Across all cell lines, we detected fivemRNA species (a1.1, a1.3, a2.3, a3.1, a5.3; Figure 3C) pre-
dicted to code for four LXRa protein variants (a1, a2, a3, a5) and two coding for LXRb (b1, b4; Figure 3D).
LXRa5 and LXRb4 have not been reported in the literature previously.
a1 transcripts were dominant (50–80% of all LXRa) in HEPG2 and TNBC cells (Figure 3C: note black and dark
gray sections corresponding to a1.1 and a1.3, respectively). In the ER+ cell lines, a5 (40–50%) and a3 (30–
40%) were the majority species (Figure 3C: note light gray and white sections corresponding to a5.3 and
a3.1, respectively). a2 comprised between 5 and 20% depending on the cell line (Figure 3C: hatched sec-
tions). LXRb1.1 was detected in all BCa cell lines, with a very small amount of b4 transcript found in HEPG2
and the ER+ cell lines only (Figure 3D). We successfully detected over 90–100% of all the LXR variants
(harboring the exon 9–10 and 7–8 junctions) present in the cell lines. From these data, we concluded
that full-length a1 was the dominantly expressed variant in TNBC cells, truncated a5 was the dominant
LXRa isoform in ER-positive cells, and b1 was the dominant LXRb transcript across all cell types.
We next performed immunoblotting to establish the range of protein variants present. Representative
blots and densitometry analysis show that bands corresponding to predicted sizes of LXRa1 (z50kDa)
and LXRb1 (z55kDa) were robustly and reproducibly detected in all cell lines (Figures 3E and 3F, respec-
tively). However, optimization of immunoblotting experimental conditions, including antibody choice, indi-
cated that multiple additional bands were present when probing for LXRa (Figure 3E). These bands closely
corresponded to sizes of proteins that would be coded by the transcripts identified above, namely a1
(50 kDa), a2 (44 kDa), a3 (46 kDa), and a5 (39 kDa). The cell line-specific pattern of protein expression
matched that of the transcript expression; a1 RNA and protein were highly expressed in HEPG2 and the
TNBC cell lines, while a5 was dominant in the ER+ cells (Figure 3G). For LXRb, only a single isoform b1
was present at both RNA and protein level (Figure 3H).4 iScience 24, 103212, October 22, 2021
Figure 3. Diversity of LXR splice variants in breast cancer cell line panel
(A and B) RNA analyses of total LXRa (A) and LXRb (B) expression.
(C and D) The stacked bar graphs show LXRa (C) and LXRb (D) transcript variants normalized to ubiquitously expressed
exon-exon junctions. Asterisks denote ambiguous amplicons.
(E and F) Representative blots and densitometry of LXRa (E) and LXRb (F) protein variants observed in cell lines.
(G and H) Pie charts show contribution of each transcript variant and protein variant to the total amount of LXRa (G) and
LXRb (H). All data shown are mean of three independent replicates with SEM. Statistical significance was measured by




ArticleWe concluded that in TNBC cell lines, full-length LXRa1 is the most abundant isoform comprising
50–80% of LXRa protein (depending on cell line), with two a1 transcript variants accounting for
51–75% of LXRa transcript. LXRa3, which lacks part of the AF-1 domain and has diminished response
to ligand (Chen et al., 2005), was the next most abundant producing 15–30% of the protein and
8–27% of the transcript. LXRa2, which is non-responsive to ligand (Chen et al., 2005), made up
8–20% of the total LXRa protein coded by two transcripts producing 7–12% of the LXRa coding
RNA. Only a small amount of LXRa5 was detected in TNBC (<10% in MDA.MB.453 cells and undetected
in other TNBC lines). Interestingly, this ‘‘double-truncation’’ variant that lacks both the AF-1 region of
a3 and the LBD region of a2 was the most abundant isoform in ER+ cells at protein (35–70%) and tran-




ArticleLXR splice variant expression and clinical significance in triple-negative breast cancer
To evaluate LXR variant expression and significance in clinical samples, LXR protein expression was
measured in a cohort of 38 fresh-frozen TNBC tumor samples (mean follow-up of three years), which has
been reported previously (Hutchinson et al., 2019; Solheim et al., 2019) (Table S3). Patients were dichoto-
mized into two groups: ‘‘No Event’’ patients defined as those who were alive and disease free at the time of
last reporting or had died from unrelated reasons; ‘‘Event’’ patients were those who had died from their
disease and/or had disease recurrence. Representative blots are shown in Figure 4A. Event patients had
significantly higher expression than ‘‘No Event’’ patients of both full-length isoforms (a1: p < 0.0001; a4:
p = 0.001; Figure 4B). Together, a1 and a4 comprised 70% of the total LXRa protein in the ‘‘No Event’’
group, but this rose to 93% in the ‘‘Event’’ group (Figure 4C). No significant difference was observed in
the level of a2, a3, a5, b1, or b4 protein variants between groups (Figure 4B).
When patients were dichotomized using Receiver Operating Characteristic (ROC) analysis, high protein
expression of the full-length variants were, as expected, found associated with significantly shorter DFS (a1:
p = 0.0005; a4: p = 0.0079; Figure 4D). Interestingly, in this more nuanced analysis, high expression of a5
(p = 0.044), LXRb1 (p = 0.0023), and LXRb4 (p = 0.037) was associated with significantly longer DFS (Figure 4E).
Furthermore, dichotomizing based on RNA expression also indicated that high expression at the transcript
level was associated with longer or shorter DFS in the same pattern as found for the protein (see Figure S9A).
In addition, a3.1, which codes for intact LBD but harboring a deletion in the AF1 domain, was also associated
with shorter DFS (p = 0.022; Figure S9A). The a2.3 transcript, which codes for a protein with the same LBDdele-
tion as a5 was, like a5, associated with longer DFS (p = 0.031; Figure S9A). a2 and a3 protein were not asso-
ciated with DFS (see Figure S9B). We concluded that full-length LXRa isoforms may exacerbate disease
severity, whereas those lacking the full LBD or LXRb isoforms were associated with reduced disease severity.Validation of isoform identity
Bands representing LXR variants were reduced by targeted siRNA
To confirm if the protein bands were LXRa variants, we first performed siLXRa treatments in cell lines. Using
previously validated (Hutchinson et al., 2021) siRNA duplexes (Origene trisilencers) against LXRa and LXRb,
we found that the protein bands predicted by size to be a1, a2, a3, a5, and b1 were all significantly reduced
by targeted siRNA in all cell lines tested (all p < 0.05; Figure S10). Note that a4 and b4 were not expressed in
cell lines and so could not be validated in this way. Furthermore, siLXRa did not reduce LXRb expression
and siLXRb did not reduce expression of any LXRa isoform, and, as is characteristic of LXRs (Chen et al.,
2005; Prüfer and Boudreaux, 2007), all protein variants were localized in the nucleus (see Figure S11).Unique peptides representing a4 and b1 were identified by MS S-trap mass
spectrophotometry
As was the case for cell line analyses, confirmation of the identity of the observed protein variants in tumor
tissue was important, especially having identified the a4 variant which has not previously been reported in
the literature. As siRNA application was not possible on the tumor samples, we performed S-trap (Hayoun
et al., 2019) coupledmass spectrometry (St-MS) in cell line and tumor lysates samples selected to represent
as much of the diversity in LXRa (Tables 1 and S4) and LXRb (Tables 2 and S5). This included two tumors in
duplicate: ligand-treated MDA.MB.468 cells (see Figure S12A) and in siCON, siLXRa, and siLXRb (see Fig-
ure S12B). We found 15 peptides uniquely corresponding to a4 BLAST sequence alignment indicated they
were high-quality hits (100% identity), including the two first exons coding for the alternative AF1 domain in
this isoform (see Figure S12C – boxed amino acids) supporting our prior conclusion that a4 was expressed
in some tumor samples. Unique peptides of b1 were also detectable in our tumor sample (see Figure S12D
– boxed amino acids). However, unique peptides corresponding to a1, a2, a3, a5, or b4 were not produced
by our enzymatic cleavage, and in silico analysis indicated these isoforms would not be distinguishable
from each other (Table3). Our next approach was to perform immunoprecipitation. We found this success-
fully enriched each isoform (see Figure S12E), but limited amounts of tumor meant bands could not be visu-
alized for excision on Coomassie gels. We concluded that a4 and b1 were present in tumor tissue.Transcript-protein correlation analysis
It was not possible to detect unique peptides for all LXR splice variants using MS. As an alternative
approach, we performed linear correlation analysis between RNA and protein expression of each variant
in all cell lines (see Figure S13) and all primary breast tumor samples (see Figure S14). The primers used6 iScience 24, 103212, October 22, 2021
Figure 4. LXRa1 and LXRa4 are highly expressed in patients with TNBC with poor survival
(A) Representative blots showing the LXR splicing events in tumors derived from 38 patients with TNBC, who were either free from disease (No Event; n = 23)
or who had relapsed or died (Event; n = 15) after follow-up (A).
(B) Differential expressions of LXRa and LXRb protein variants in No Event and Event groups were plotted in box and whiskers charts (B). The line shows the
median value, the box shows 10th to 90th percentile, and whiskers show minimum-to-maximum values. Statistical analysis was established using multiple t-
tests with Holm-Sidak for multiple correction; p % 0.05 was considered significant.
(C) Pie charts show contribution of each transcript variant and protein variant to the total amount of LXRa in No Event and Event patients (C).
(D and E) Kaplan-Meier survival curves plotting disease-free survival of patients with TNBC dichotomized based on protein expression of full-length LXRa1
and LXRa4 transcripts (D) or truncated LXRa5 and LXRb1 and LXRb4 (E). All protein measured relative to HPRT. Data derived from the mean of two different




Articleto detect different RNA species were usually specific to a single variant, but it was not possible to design
unique primers for every variant. We hypothesized that where detection was ambiguous, RNA expression
should correlate with expression of the protein for which it coded, thus identifying the correct RNA species
and validating the protein isoform previously assigned only by mass/charge. Linear correlation analysis was
performed in the seven cell lines comparing expression of each transcript variant against each protein bandiScience 24, 103212, October 22, 2021 7















3500 52.32 13% Q.AQ(+.98)GGSSC(+57.02)ILR.E No 32 41
A.QGGSSC(+57.02)ILR.E No 33 41
R.MPHSAGGTAGV.G No 46 56
R.ASSPPQ(+.98)ILPQ.L No 196 205
R.ASSPPQILPQLSPEQ(+.98)LGMIEK.L No 196 216
R.AMN(+.98)ELQLN(+.98)DAEFALLI.A No 345 360
Tumor 2
Rep 2
3971 58.66 22% K.C(+57.02)RQ(+.98)AGM(+15.99)
REEC(+57.02)VLSEEQ(+.98)IRLK.K
No 158 177
R.QEEEQAHATSLPPR.A No 182 195
R.ASSPPQILPQLSPEQ(+.98)LGMIEK.L No 196 216
L.SPEQ(+.98)LGMIEK.L No 207 216
G.M(+15.99)IEKLVAAQQ(+.98)Q(+.98).C No 213 223
K.QLPGFLQLSR.E No 274 283
Q.VEFINPIFEFSR.A No 333 344
R.AMNELQLNDAEFALLI.A No 345 360
Tumor 5
Rep 1




Yes [a4] 14 1
59.30
[LXRa homolog]
16% R.AEPPSEPTEIRPQ(+.98)K.R No 70 83
KC (+57.02)RQAGMR.E No 196 208
R.ASSPPQILPQLSP.E No 196 208
R.ASSPPQILPQLSPEQ(+.98)LGMIEK.L No 196 216
G.MIEKLVAAQQQC(+57.02)NRR.S No 213 227
K.TSAIEVMLLETSRRYN(+.98)PG.S No 292 309
Tumor 5
Rep 2
3412 38.73 9% C.VLSEEQIR.L No 168 175
R.ASSPPQILPQLSPEQ(+.98)LGMIEK.L No 196 216
R.ASSPPQ(+.98)ILPQ.L No 196 205
R.EDQIALLK.T No 284 291




Articlefor which it could potentially code. There was a strong and significant positive correlation between tran-
script variants and the protein isoform for which they were predicted to code: a1 protein correlated with
a1.1 (R2 = 0.97; p < 0.0001; Figure S13 top row) and a1.3 (R2 = 0.78; p = 0.0084; Figure S13 top row). b1 pro-
tein correlated with b1.1 transcript (R2 = 0.99; p < 0.0001; Figure S13 bottom row). During primer design it
became clear that due to complexity arising from the large number of LXR coding transcripts, several tran-
scripts were not distinguishable from each other due to sequence homology (denoted with asterisks in Fig-
ure 3C). Specifically, indistinguishable transcripts were a1.4 and a2.3; a3.1 and a5.1; and a3.3 and a5.3. We
tested all potential protein isoforms for correlation with the ambiguous primer pairs: a1.4/a2.3 correlated
with a2 protein (p = 0.0022; R2 = 0.97; Figure S13 row 2) but not a1 protein (p > 0.05); a3.1/a5.1 correlated
with a3 protein (p = 0.034; R2 = 0.63; Figure S13 row 3) but not a5 protein (p > 0.05); and a3.3/a5.3 corre-
lated with a5 protein (p = 0.029; R2 = 0.65; Figure S13 row 4) but not a3 protein (p > 0.05). We also designed
primers against the exon 5 and 7 junction to simultaneously recognize the a2 and a5 variants that lack exon
6 and a portion of the LBD. These a2/a5 primers detected RNA that correlated with a5 protein (p = 0.0065;
R2 = 0.8; Figure S13 fourth row) but not with a2 (p > 0.1; Figure S13 second row).
Next, although cytoplasmic extraction was not possible in frozen tumor samples as they had lost cellular sub-
structure in the freezing process, given the number of replicates was larger (n = 38), we considered testing for8 iScience 24, 103212, October 22, 2021















3500 46.60 7% L.MIQQLVAAQ.L No 226 234
Q.Q(+.98)LVAAQLQC(+57.02)NK.R No 229 239
Q.VEFINPIFEFSR.A No 346 357
K.RPQDQ(+.98)LR.F No 410 416




K.VTPWPLGADPQSR.D Yes [b1] 248 260
K.RPQDQ(+.98)LR.F No 410 416
Tumor 5
Rep 1
3713 56.33 14% R.SVVRGGAR.R No 113 121
E.LM(+15.99)IQQ(+.98)LVAAQ.L No 225 234
V.QLTAAQ(+.98)ELMIQ(+.98).Q No 218 228
Q.Q(+.98)LVAAQLQC(+57.02)NK.R No 229 239
K.RSFSDQ(+.98)PK.V No 240 247
K.VTPWPLGADPQ(+.98)SR.D Yes [b1] 248 260
A.LQQ(+.98)PYVEALLS.Y No 394 404
E.ALLSYTR.I No 401 407
Tumor 5
Rep 2
3412 59.82 20% R.RSVVRGGAR.R No 113 121




E.GVQLTAAQ(+.98)ELMIQ.Q No 216 228




K.RSFSDQ(+.98)PK.V No 240 247
R.EDQIALLK.A No 297 304
A.LQQ(+.98)PYVEALLS.Y No 394 404
K.RPQDQ(+.98)LR.F No 410 416




Articlecorrelations a reasonable approach (see Figure S14). As for cell lines, both a1.1 and a1.3 correlated with a1
protein (p < 0.05 for both); a2.3 correlated with a2 protein (p = 0.036); a3.1 correlated with a3 protein (p =
0.056); a4.1 correlated with a4 protein (p = 0.0037; note, this variant was not detected in cell lines); and a5.3
(p = 0.039) and a2/a5 (p = 0.054) correlatedwith a5 protein. For LXRb, b1.1 transcript correlatedwith b1 protein
(p = 0.022). b3 and b4 are almost identical in size (46 and 47 kDa, respectively) and so are indistinguishable by
immunoblotting. b4 transcript (p = 0.031) but not b3 (p > 0.05) correlatedwith the band corresponding to b3/b4
protein (see Figure S14 bottom row) confirming this as LXRb4. The correlative analysis we performed here, in
combination with our other validation experiments, allows high confidence that the splice variants had been
correctly identified. In combination with the siRNA in the cell line studies above and MS experiments, these
correlative observations indicate that five LXRa variants and two LXRb variants are expressed in TNBC.LXR splice variants are differentially correlated with expression of target genes in Event and
No Event patients
We previously reported that LXRa expression is positively correlated to target gene expression in ER-nega-
tive patients who had relapsed and/or died due to their disease (Event patients) but not those who surviveiScience 24, 103212, October 22, 2021 9











(after trypsin digestion)Start End
a1 a2 1607.8137 1 15 2 MSLWLGAPVPDIPPD
1348.7140 293 300 6 SAIEVMLLETSR
a2 a5 1148.6343 235,236-297 300 5/7 VT-VMLLETSR
a3 a5 2307.1761 46 69 3 MPHSAGGTAGVGLEAAEPTALLTR
a4 – 1550.7090 14 1 -1d MQQTSWNPLGGTCK
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b1 1423.7328 248 260 Exon6/ VTPWPLGADPQSR
1475.7892 268 279 exon7abc FAHFTELAIISVQ
b3 1021.5564 249–280 286 Exon6/exon7b V-TEIVDFAK
b4 545.3405 249–293 299 Exon6/Exon 7c V-TLGREDQ
Amino acids position number based on a1 and/or b1 amino acid numbering position. Amino acid numbering position with ‘‘-’’ indicates the additional amino
acid(s) coming before a1 and/or b1’s amino acid position number 1. The numerical exons represent the first discovered exons. The numerical exons followed




Articledisease free (No Event patients) (Hutchinson et al., 2021). Here, we tested the hypothesis that differential
LXR splice variant expression between cancers may contribute to disease etiology via their ability to control
expression of gene targets. Two canonical LXR target genes representing LXR’s roles in cholesterol meta-
bolism (ABCA1) and chemoresistance (ABCB1) were tested for correlations with LXR splice variant expres-
sion (Hutchinson et al., 2021; Pan et al., 2019).
Expression of both full-length isoforms (a1 and a4) positively correlated with expression of ABCA1 and
ABCB1 but interestingly only in Event patients (p < 0.05 for all; Figure 5). Strikingly, expression of b1 was
inversely correlated with both ABCA1 and ABCB1 but only in No Event patients (p < 0.05; Figure 5). Statis-
tically significant correlations between a2, a3, or a5 with target genes were not observed (see Figure S15).
From these data, we concluded that while full-length LXRa is associated with activation of gene targets in
patients who relapse or die; LXRb is associated with inhibition of the same target genes in TNBC survivors.
DISCUSSION
The objective of this study was to establish the repertoire, expression levels, and pathophysiological sig-
nificance of LXR splice variants in BCa. In TNBC, we found evidence that five LXRa and two LXRb splice var-
iants are expressed at RNA and protein levels. Three of these isoforms, a4, a5, and b1, are new to the liter-
ature and do not have validated UNIPROT records. Our data demonstrate that LXR splice variants have
clinical significance in TNBC; full-length LXRa (a1 and a4) is associated with shorter DFS, while LXRb and
LXRa variants with truncated ligand-binding domains were associated with longer DFS.
This current study’s findings may provide preliminary evidence for oncogenic or tumor suppressive func-
tions of LXR splice variants. High expression of the full-length a1 was strongly associated with shorter
DFS at both transcript and protein level. High expression of two other isoforms, a3 (transcript only) and
a4 (transcript and protein), were also associated with shorter DFS. Although both have disruptions to their
AF1 domains, they are otherwise homologous to full-length a1, including, importantly, an uninterrupted10 iScience 24, 103212, October 22, 2021
Figure 5. Protein expression of LXR variants is differentially associated with LXR target gene expression in TNBC
tumors
Patients with TNBC (n = 38) were divided into two groups: no event (n = 23) and event (n = 15) based on disease-free
survival status. Linear regression was used to determine if the slope of the lines were significantly different from 0 (p %
0.05). Line of best fit is shown if the relationship was significant. Circles represent mean protein expression of two tumor




ArticleLBD. a5 skips the same exons as a2 and a3 and has the same deletions; 60 amino acids are missing from the
LBD, and 45 amino acids of the AF1 domain are missing, respectively. These truncations have been shown
separately to diminish (a3) or completely abolish (a2) transcriptional activity (Chen et al., 2005). Interest-
ingly, high transcript expression of a2 was, like a5, linked to longer DFS. High a3 transcript on the other
hand, like full-length a1 and a4, was linked to shorter DFS. These observations suggest that splice variants
with disrupted LBD are advantageous, but the protein can tolerate disruption or even partial deletion of the
AF1 domain and still be associated with worse prognosis. b1 (P55055-1) and b4 (M0R2F9) are generated by
the mutually exclusive inclusion or exclusion of exon 7, again leading to a change in the LBD. With LXRb
however, high expression of either b1 or b4 was linked to longer DFS. The cellular role of this altered
LBD remains to be determined.
Belorusova et al. reported peptides of LXRa comprising theH3 andpartial part of H5 correlated to high ABCA1
expression (Belorusova et al., 2019). In addition, the differential relationship between target genes and LXRa
isoforms in different patient groups also points to an oncogenic role for LXRa and a tumor suppressor role for
LXRb in TNBC tumors. Indeed, a beneficial role for LXRb has been reportedpreviously, albeit in non-TNBC sub-
types. Both dendrogenin A and RGX-104 are tumor suppressors and selective LXRb agonists (Poirot and
Silvente-Poirot, 2018; Segala et al., 2017; Tavazoie et al., 2018). An understanding of the effect of these com-
pounds on TNBC cells and tissue would help delineate if LXRb or LXRa are predominant (given LXRb’s higher
expression levels) and if LXRb is also a therapeutic target in TNBC disease. LXRbmay be the predominant iso-
form in TNBC and is normally able to supress LXRa signaling due to its expression levels. However, functional
activity cannot be inferred by isoform expression only and other mechanisms of differential LXR isoform regu-
lation are likely to be at play. For example, post-translationalmodifications, particularly at the S198 residue (Wu
et al., 2015), canmodify LXR transactivation potential. Our previous work found that co-factor expression levels




Articleaccessibility could differentially alter the ability of the LXR isoforms to bind to target gene promoters. Endog-
enous ligand synthesis may also be important. Several non-cancer cell types found in the TNBC tumor micro-
environment such as macrophages (Blanc et al., 2013), adipocytes (Li et al., 2014), and fibroblasts (Axelson and
Larsson, 1995) are potent converters of cholesterol to oxysterols. Whether these cells drive activation of LXR
isoforms in the adjacent tumor cells through paracrine or juxtacrine secretion of ligand has, to date, not
been reported in the literature. Indeed, a key limitation of the current study is that it was not possible to estab-
lish if a single cell, or cell type, was expressing multiple or single splice variants. This would provide a mecha-
nism where the cell could fine-tune its response to ligand.
To the best of our knowledge, a4 (NM_001934; NP_001238863; B4DXU5), a5 (NM_001363595.2;
NP_001350524.1; B5MBY7), and b4 (M0R2F9) have not been reported in the literature before. a4 has an
alternative 21 amino acids in the start of the AF1 domain producing a unique peptide mass signature
that was detected with MS. These data support its inclusion in UNIPROT with a Q13133 prefix. As this
variant has not been investigated before and we perform no functional studies herein, the significance
of this partial AF1 substitution remains unknown. a5 was not detected by MS, but its presumed protein
band (39 kDa) was lost after siLXRa treatment, its transcript was robustly expressed, and protein and tran-
script expression were strongly correlated. Although a unique peptide for b4 was predicted from in silico
analyses, it was not detected with MS; however, its transcript was robustly expressed, and protein and tran-
script expression were strongly correlated.
Some of our results are at odds with prior observations. We were unable to detect expression of XP_02430405X
(previously termed a4 (Endo-Umeda et al., 2012)), in any cell lines or tissues, at RNA or protein level, including in
HEPG2 or MCF7 cell lines that were previously shown to express this isoform (Bunay et al., 2020; Endo-Umeda
et al., 2012). Intriguingly, a variant previously reported to be a5 (Bunay et al., 2020; Endo-Umeda et al., 2012) did
not correspond to any of the 64 LXRa transcripts fromNCBI nor any LXRa UNIPROT entries. In this study (Endo-
Umeda et al., 2012), the measurement of XP_02430405X and previously reported a5 relied on PCR primers that
detected a retained intron between exon 6–7 and a retained intron between exon 7–8, respectively (see Fig-
ure S3). We went to extensive lengths to ensure primary RNA or gDNA did not contaminate our cDNA libraries,
steps that surprisingly have not been reported in LXR splicing studies previously. Cytoplasmic RNA is preferred
over total cell isolates when examining splice expression, and this has been reported previously to increase
sensitivity of splice junction detection (Zaghlool et al., 2013). Previous detection of XP_02430405Xmay therefore
bedue toamplificationof incompletely processed transcripts or contaminatinggDNA.Duringour primer design
stage, we found that the PCR primers previously used tomeasure a1 at the exon 2–3 junction (Chen et al., 2005;
Endo-Umeda et al., 2012; Rondanino et al., 2014) also detect a2 (see Figure S3). In addition, primers previously
used tomeasure a2 at the exon 5–7 junction (Chen et al., 2005; Endo-Umeda et al., 2012; Rondanino et al., 2014)
also detect the previously unreported a5 variant (see Figure S3). Our correlation analyses in cell lines and primary
tumor samples suggest themajority of exon 6 skipping transcripts actually code for a5 not a2. We also found a5
is significantly (20-fold) higher than a2 inMCF7 and equal to a2 in HEPG2, the same cell lines that in prior studies
were used to show a2 was strongly expressed. It is likely that previous reports have over-estimated the contri-
bution of a2 and under-estimated the contribution of a5 to the LXR pool.
In summary, this study provides critical insight into the pathophysiology of LXR splicing in BCa. Our data are
consistent with the hypothesis that full-length LXRa is oncogenic but LXRb and truncated LXRa variants may
suppress tumor development. Functional studies should help resolve if the LXRs are drivers of tumor path-
ophysiology or simply passengers. We propose the existence of two new LXRa isoforms: a4 containing an
alternative AF1 region and a5 which lacks large sections of the AF1 and LBD regulatory regions. TNBC is
defined as a category of exclusion. The data presented here suggest that measuring LXRa1, LXRa5, and
LXRb at RNA or protein level may allow sub-stratification of patients with TNBC for increased accuracy
of prognosis. Perhaps more importantly, given the array of pharmacological and dietary modulators of
the LXR pathway, defining gene networks regulated by the opposing oncogenic and tumor suppressor
LXR variants will aid in the development of lifestyle and pharmacological interventions to reduce incidence
and improve survival in this challenging cancer of unmet clinical need.Limitations of the study
There were three important limitations of this study. It was not possible to separate all novel (or canonical)
LXR isoforms using S-trap mass spectrometry alone. Secondly, limiting tissue amounts meant some exper-




Articletarget genes such as SREBP and APOE. The limited tissue also meant LXR purification with immunoprecip-
itation and/or Coomassie approaches prior to mass spectrometry was not feasible. This would have al-
lowed us to assign LXR-specific peptides as belonging to different LXR proteins that had been identified
by mass-charge analysis with western blotting, for example, b4. Finally, as mentioned above, isoforms
a4 and b4 were identified in tumor tissue but not BCa cell lines. It is possible that the source of these iso-
forms is non-tumor cells of the tumor microenvironment, such as fibroblasts, adipocytes, or immune infil-
trate, and not the tumor cells per se. Cell sorting with cell surface markers of freshly collected tumor sam-
ples is required to delineate the source of these primary material isoforms specifically.
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Åkerblad, P., and Lindstedt, E.-L. (2019).
Structural analysis identifies an escape route from
the adverse lipogenic effects of liver X receptor
ligands. Commun. Biol. 2, 1–13.
Blanc, M., Hsieh, W.Y., Robertson, K.A., Kropp,
K.A., Forster, T., Shui, G., Lacaze, P., Watterson,
S., Griffiths, S.J., Spann, N.J., et al. (2013). The
transcription factor STAT-1 couples macrophage
synthesis of 25-hydroxycholesterol to the
interferon antiviral response. Immunity 38,
106–118. https://doi.org/10.1016/j.immuni.2012.
11.004.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L.,
Torre, L.A., and Jemal, A. (2018). Global cancer
statistics 2018: GLOBOCAN estimates of
incidence and mortality worldwide for 36 cancers
in 185 countries. CA: Cancer J. Clinic. 68,
394–424.
Broad, R.V., Jones, S.J., Teske, M.C., Wastall,
L.M., Hanby, A.M., Thorne, J.L., and Hughes, T.A.
(2021). Inhibition of interferon-signalling halts
cancer-associated fibroblast-dependent
protection of breast cancer cells from
chemotherapy. Br. J. Cancer 124, 1110–1120.
https://doi.org/10.1038/s41416-020-01226-4.
Bunay, J., Fouache, A., Trousson, A., de
Joussineau, C., Bouchareb, E., Zhekun, Z., Kocer,
A., Morel, L., Baron, S., and Lobaccaro, J.-M.A.
(2020). Screening for Liver X Receptor
modulators: where are we and for what use? Br. J.
Pharmacol. 178, 3277–3293.
Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E.,
Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne,
C.J., Heuer, M.L., and Larsson, E. (2012). The cBio14 iScience 24, 103212, October 22, 2021Cancer Genomics Portal: An Open Platform for
Exploring Multidimensional Cancer Genomics
Data (AACR).
Chen, M., Beaven, S., and Tontonoz, P. (2005).
Identification and characterization of two
alternatively spliced transcript variants of human
liver X receptor alpha. J. Lipid Res. 46, 2570–2579.
https://doi.org/10.1194/jlr.M500157-JLR200.
Cioccoloni, G., Soteriou, C., Websdale, A., Wallis,
L., Zulyniak, M.A., and Thorne, J.L. (2020).
Phytosterols and phytostanols and the hallmarks
of cancer inmodel organisms: a systematic review
and meta-analysis. Crit. Rev. Food Sci. Nutr. 1, 21.
https://doi.org/10.1080/10408398.2020.1835820.
Davis, M.W. (2012). ApE—a Plasmid editor.
Endo-Umeda, K., Uno, S., Fujimori, K., Naito, Y.,
Saito, K., Yamagishi, K., Jeong, Y., Miyachi, H.,
Tokiwa, H., Yamada, S., andMakishima,M. (2012).
Differential expression and function of alternative
splicing variants of human liver X receptor alpha.
Mol. Pharmacol. 81, 800–810. https://doi.org/10.
1124/mol.111.077206.
Gasteiger, E., Hoogland, C., Gattiker, A., Duvaud,
S., Wilkins, M., Appel, R., and Bairoch, A. (2003).
The Proteomics Protocols Handbook: Protein
Identification and Analysis Tools on the ExPASy
Server (Humana Press).
Hashimoto, K., Ishida, E., Matsumoto, S.,
Shibusawa, N., Okada, S., Monden, T., Satoh, T.,
Yamada, M., and Mori, M. (2009). A liver X
receptor (LXR)-b alternative splicing variant
(LXRBSV) acts as an RNA co-activator of LXR-b.
Biochem. Biophys. Res. Commun. 390, 1260–
1265.
Hayoun, K., Gouveia, D., Grenga, L., Pible, O.,
and Armengaud, J. (2019). Evaluation of sample
preparation methods for fast proteotyping of
microorganisms by tandem mass spectrometry.
Front. Microbiol. 10, 1985.
Hudis, C.A., and Gianni, L. (2011). Triple-negative
breast cancer: an unmet medical need.
Oncologist 16, 1–11.
Hutchinson, S.A., Lianto, P., Roberg-Larsen, H.,
Battaglia, S., Hughes, T.A., and Thorne, J.L.
(2019). ER-negative breast cancer is highly
responsive to cholesterol metabolite signalling.
Nutrients 11, 2618. https://doi.org/10.3390/
nu11112618.
Hutchinson, S.A., Websdale, A., Cioccoloni, G.,
Roberg-Larsen, H., Lianto, P., Kim, B., Rose, A.,
Soteriou, C., Pramanik, A., Wastall, L.M., et al.
(2021). Liver x receptor alpha drives
chemoresistance in response to side-chain
hydroxycholesterols in triple negative breast
cancer. Oncogene 40, 2872–2883. https://doi.
org/10.1038/s41388-021-01720-w.
Jiang, L., Zhao, X., Xu, J., Li, C., Yu, Y., Wang, W.,
and Zhu, L. (2019). The protective effect of dietary
phytosterols on cancer risk: a systematic meta-
analysis. J. Oncol. 2019, 11. https://doi.org/10.
1155/2019/7479518.
Laffitte, B.A., Joseph, S.B., Walczak, R., Pei, L.,
Wilpitz, D.C., Collins, J.L., and Tontonoz, P.
(2001). Autoregulation of the human liver Xreceptor a promoter. Mol. Cell. Biol. 21, 7558–
7568.
Li, B., and Dewey, C.N. (2011). RSEM: accurate
transcript quantification from RNA-Seq data with
or without a reference genome. BMC Bioinform.
12, 1–16.
Li, J., Daly, E., Campioli, E., Wabitsch, M., and
Papadopoulos, V. (2014). De novo synthesis of
steroids and oxysterols in adipocytes. J. Biol.
Chem. 289, 747–764. https://doi.org/10.1074/jbc.
M113.534172.
Liu, B., Yi, Z., Guan, X., Zeng, Y.X., and Ma, F.
(2017). The relationship between statins and
breast cancer prognosis varies by statin type and
exposure time: a meta-analysis. Breast Cancer
Res. Treat. 164, 1–11. https://doi.org/10.1007/
s10549-017-4246-0.
Nelson, E.R., Wardell, S.E., Jasper, J.S., Park, S.,
Suchindran, S., Howe, M.K., Carver, N.J., Pillai,
R.V., Sullivan, P.M., and Sondhi, V. (2013). 27-
Hydroxycholesterol links hypercholesterolemia
and breast cancer pathophysiology. Science 342,
1094–1098.
Pan, H., Zheng, Y., Pan, Q., Chen, H., Chen, F.,
Wu, J., and Di, D. (2019). Expression of LXR-b,
ABCA1 and ABCG1 in human triple-negative
breast cancer tissues. Oncol. Rep. 42, 1869–1877.
Perou, C.M., Sørlie, T., Eisen, M.B., Van De Rijn,
M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., Ross,
D.T., Johnsen, H., and Akslen, L.A. (2000).
Molecular portraits of human breast tumours.
Nature 406, 747–752.
Poirot, M., and Silvente-Poirot, S. (2018). The
tumor-suppressor cholesterol metabolite,
dendrogenin A, is a new class of LXR modulator
activating lethal autophagy in cancers. Biochem.
Pharmacol. 153, 75–81. https://doi.org/10.1016/j.
bcp.2018.01.046.
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KEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
LXRa R&D System Cat. PP-PPZ0412-00; RRID:AB_2154888
LXRb Active Motif Cat. 61177; RRID:AB_2614980
HPRT Santa Cruz Cat. Sc-376938; RRID: n/a
IRDye 800CV goat anti-mouse LI-COR Biosciences Cat. 926-68170; RRID:AB_10956589
IRDye 680RD goat anti-rabbit LI-COR Biosciences Cat. 926-68071; RRID:AB_10956166
Isotype IgG2a Cell Signalling Cat. 61656S; RRID:AB_2799613
Biological samples
Frozen tumor samples (n=38), see Table S3 Leeds Breast Research Tissue Bank Ethic approval ID: 15/HY/0025 and
LBTB_TAC_1/17
Chemicals, peptides, and recombinant proteins
Dulbecco’s Modified Eagle Medium (DMEM) Thermo Fisher Cat. 31966047
Fetal Bovine Serum (FBS) Thermo Fisher Cat. 11560636
Lipofectamine RNAiMAX Thermo Fisher Cat. 13778030
OptiMeM Thermo Fisher Cat. 31985062
bis(sulfosuccinimidyl)suberate Thermo Fisher Cat. A39266
GW3965 Tocris Cat. 2474
Dynabeads Protein A Thermo Fisher Cat. 100002D
PMSF protease and phosphatase inhibitor Thermo Fisher Cat. 78440
NUPAGE LDS sample loading buffer Thermo Fisher Cat. NP0007
DTT reducing agent Thermo Fisher Cat. NP0004
TBS blocking buffer Li-COR Cat. 927-60001
Critical commercial assays
ReliaPrepTM RNA Cell Miniprep System Promega Cat. Z6012
Cytoplasmic & Nuclear RNA Purification Kit Norgen Cat. 21000
GoScriptTM Reverse Transcription kit Promega Cat. A5003
BCA kit Thermo Fisher Cat. 23227









CONTROL siRNA Origene Cat. SR30004
siLXRa Origene Cat. SR322981
siLXRb Origene Cat. SR305039
Primers for qPCR, see Table S4 This paper N/A
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Software and algorithms
Clustal Omega-Multiple sequence alignment EMBL-EBI https://www.ebi.ac.uk/Tools/msa/clustalo/
PeptideMass tool Swiss Institute of Bioinformatics http://www.expasy.org/tools/peptide-mass.
html
Diagram Venn Bioinformatics & Evolutionary Genomics http://bioinformatics.psb.ugent.be/webtools/
Venn/
GraphPad Prism v8 GraphPad Software https://www.graphpad.com/scientific-
software/prism/
Image StudioTM Lite LI-COR Biosciences https://www.licor.com/bio/image-studio/




NCBI National Center for Biotechnology Information https://www.ncbi.nlm.nih.gov
ENSEMBL European Bioinformatics Institute (EMBL-EBI) https://www.ensembl.org/index.html
UNIPROT EMBL-EBI, Swiss Institute of Bioinformatics
(SIB), and Protein Information Resources (PIR)
https://www.uniprot.org
cBioportal Memorial Sloan Kettering Cancer Center https://www.cbioportal.org








Further information and requests for resources, reagents, data, and/or experimental protocols reported in
this paper should be directed to and will be fulfilled by the lead contact, Dr James L Thorne (J.L.Thorne@
leeds.ac.uk).
Materials availability statement
There are restrictions to the availability of Tumor tissues due to MTA restrictions and limiting sample
amounts. This study did not generate other unique reagents.
Data and code availability
All NGS data used in this study were freely available in public repositories at the date of publication. Links
to repositories can be found via inline citations.
EXPERIMENTAL MODELS AND SUBJECT DETAILS
Cell lines
The HEPG2, MCF7, BT474, MDA.MB.231, MDA.MB.468, MDA.MB.453, and MDA.MB.157 cell lines were
originally obtained from ATCC (Manassas, USA). Cell lines were routinely cultured in Dulbecco’s Modified
Eagle Medium (DMEM; Thermo Fisher, UK, Cat. 31966047), supplemented with 10% Fetal Bovine Serum
(FBS; Thermo Fisher, UK, Cat. 11560636) and incubated in 37C, 5% CO2. Cells were periodically checked
and confirmed to be mycoplasma free.
Human subjects
Thirty-eight frozen tumor samples were obtained with ethical approval from the Leeds Breast Research Tis-
sue Bank (15/HY/0025 and LBTB_TAC_1/17). The clinicopathological features and selection criteria of
these cohorts have been described previously (Broad et al., 2021; Hutchinson et al., 2019, 2021; Solheim
et al., 2019) (details in Table S3). All subjects were female. The Leeds TNBC tumor cohorts were grouped




Articlefollow-up (median follow-up time was 96 months) were categorized to ‘No Event’ group. Meanwhile, TNBC
patients who had relapsed and/or died due to their disease were grouped to an ’Event’ group (median
follow-up time was 20 months).
METHOD DETAILS
Systematic transcript variant analysis in public databases
The NR1H3/LXRa and NR1H2/LXRb spliced variant sequences were assessed in NCBI (Pruitt et al., 2005)
and ENSEMBL (Aken et al., 2016) databases. Sequence annotation records of LXRa and LXRb spliced
variant read from databases were stored in a feature library created with ApE plasmid editor (Davis,
2012). This feature library can then be used to scan any nucleotide and/or amino acid sequence that are
complementary to all alternative forms of the LXRa and/or LXRb sequences recorded in this library. The
number of nucleotides in each exon and intron were counted in ApE plasmid editor to determine the pro-
portions for drawing squares and lines represented exons and introns. The schematic diagrams of LXR
variant structures were drawn using AutoCAD (Autodesk, US) software are shown in Figures 1, S1 (LXRa),
and S2 (LXRb). Variants, their database links and names, and previously reported names, are listed in S1
(LXRa) and S2 (LXRb).
The cancer genome atlas (TCGA) splicing database analyses
TCGA splicing variants database (TSVdb) was searched and LXR splicing expression data in BCa tumor tis-
sue, reported as normalized RNA-Seq by Expectation Maximization (RSEM) values, were downloaded us-
ing the TSVdb webtool (http://www.tsvdb.com) (Sun et al., 2018). Unreported and/or missing clinical status
of the deposited TCGA BCa tumor samples were obtained from patient tumor sample information in cBio-
portal (http://cBioportal.org) (Cerami et al., 2012).
siRNA transfection
siRNA transfection was performed as previously reported (Thorne et al., 2018). Briefly, 1x105 cells were
plated in 6-well plates and incubated overnight. Lipofectamine RNAiMAX (Thermo Fisher, UK, Cat.
13778030), siLXRa (Origene, USA, Cat. SR322981) and siLXRb (Origene, USA, Cat. SR305039) or the scram-
bled siRNA (Origene, USA, Cat. SR30004) were diluted in OptiMeM (Thermo Fisher, UK, Cat. 31985062),
and added to the cells at a final concentration of 30 nM. The cells were incubated and after 20 h the media
was removed and fresh DMEM added. Knockdown was confirmed at the protein level 48 h post-
transfection.
mRNA extraction, cDNA synthesis, qPCR and primer design
Total RNA was isolated from approximately 53 105 cells using the ReliaPrepTM RNA Cell Miniprep System
(Promega, UK, Cat. Z6012) following product guidelines, including on column digestion of gDNA.
Cytoplasmic RNA was isolated from approximately 2 3 106 cells using the Cytoplasmic & Nuclear RNA Pu-
rification Kit (Norgen, Belmont, CA, USA, Cat. 21000). The concentration of isolated RNA was determined
spectrophotometrically, and RNA purity was evaluated by 260/230 nm and 260/280 nm ratios using a
CLARIOstar plate reader (BMG LABTECH, Germany). cDNA was synthesized from 2 mg RNA using the
GoScriptTM Reverse Transcription kit (Promega, UK, Cat. A5003). Primers were designed using NCBI
BLAST primer design or, where transcript variants were not available in the NCBI database, primer 3 soft-
ware was used (Untergasser et al., 2012). Cytoplasmic RNA was extracted to ensure only fully processed
LXR transcripts were measured. Amplicon size was restricted between 80 to 150 bp and amplicons were
required to span an exon-exon boundary. Primer efficiency was measured from qPCR standard curves,
and primers were redesigned if amplification efficiency did not fall within 90-110% and/or a single peak
was not observed in melting temperature analysis.
During primer design, it became clear that due to complexity arising from the large number of LXR coding
transcripts, several transcripts were not distinguishable from each other due to the sequence homology
and coding redundancy. Thus, some primer pairs detected ambiguous amplicons that could belong to
two or sometimes three different splice variants. This ambiguity has not been addressed in the literature
before as for example, the PCR primers previously used to measure a1 (Chen et al., 2005; Endo-Umeda
et al., 2012; Rondanino et al., 2014) also amplify a2. Primers previously used to measure a2 via the exon
6 skipping (5-7 junction) (Chen et al., 2005; Endo-Umeda et al., 2012; Rondanino et al., 2014) also detect




Articleand S2; Tables S1 and S2), any potentially ambiguous amplicons were identified and unique primer sets
against exon-exon junction could be designed for most transcript variants. Primers were designed using
NCBI BLAST primer design or, where transcript variants were not available in the NCBI database, primer
3 software was used (Untergasser et al., 2012). According to the gene sequences fromNCBI and ENSEMBL,
the amplicon size was restricted between 80 to 150 bp. The standard curve from 1-5 ug each concentration
cDNA ratio was carried to determine the efficiency of the primers. Primer pairs were chosen based on spec-
ificity (single peak in melting temperature analysis) and amplification efficiency. For the purpose of compar-
ison, we summarized primer locations used in previous studies (see Figure S3). All primer sequences used in
this study are shown in Table S6 and their locations within the LXR loci are shown graphically for LXRa in
Figure S4 and for LXRb in Figure S5.
Protein lysate extraction
Five mg fresh-frozen tumor biopsy samples were homogenized with a 1 mL Dounce tissue grinder (SLS, UK,
Cat. HOM3580). Cell pellets and/or tumor samples were lysed in RIPA buffer (10 mM Tris-HCl pH 8, 140 mM
NaCl, 0.1% SDS, 1% Triton X-100, 0.1% sodium deoxycholate, 1 mMEDTA, 0.5 mMEGTA), with 1 mM PMSF
(Thermo Fisher, UK, Cat. 78440) added fresh prior to use. The lysed pellets were incubated on ice for 5 min
and centrifuged at 11,500xg at 4C for 10 min. The protein lysates concentrations were determined using a
BCA kit (Thermo Fisher, UK, Cat. 23227) and lysates were kept in 80C until further analyses. Each tumor
sample was split in two and duplicate extractions were made. For each protein quantified both duplicates
were run and the average of each was used for analysis. Concordance of duplicates was high (see
Figure S16).
Cytoplasmic and nuclear protein extraction
For the cytoplasmic and nuclear protein extractions, the REAP (Rapid Efficient And Practical) protocol (Su-
zuki et al., 2010) was followed with a slight modification. In brief, 1 3 107 cells were suspended in 1 mL ice
cold PBS with 1 mM PMSF. 200 mL of cell lysate was taken, put into a new chilled Eppendorf tube and centri-
fuged at 1,500 rpm for 3 min at 4C. Supernatant was removed. The cell pellet (from 200 mL cell lysate) was
resuspended in RIPA buffer with 1 mM PMSF (Thermo Fisher, UK, Cat. 78440) added fresh prior to use and
labeled as a ‘‘whole cell fraction’’. The remaining 800 mL cell lysate was centrifuged at 11,5003g at 4C for
10 s. The supernatant was removed. The cell pellet (from 800 mL cell lysate) was resuspended in 200 mL ice-
cold PBS+0.1 NP40 with 1 mM PMSF and centrifuged at 11,500xg at 4C for 10 s. The supernatant was taken
into a new chilled Eppendorf tube and labeled as a ‘‘cytoplasmic fraction’’. The cell pellet was then resus-
pended in 200 mL ice-cold PBS+0.1 NP40 with 1 mM PMSF and centrifuged at 11,5003g at 4C for 10 s. The
supernatant was removed and cell pellet resuspended in 50 uL RIPA buffer with 1 mM PMSF. Cell lysate was
sonicated with a water-bath sonicator (Diagenode Bioruptor Pico, Belgium, Germany) with cycles of 10 s on
and 10 s off for five cycles, followed by centrifugation at 11,500 g at 4C for 10 min. The supernatant was
taken, put into a new chilled Eppendorf tube, and labeled as a ‘‘nuclear fraction’’. The protein lysates con-
centrations were determined using a BCA kit and lysates were kept in 80C until further analyses.
Immunoblotting
Forty-five micrograms of protein lysate combined with NUPAGE LDS sample loading buffer (Thermo
Fisher, UK, Cat. NP0007) and DTT reducing agent (Thermo Fisher, UK, Cat. NP0004) was heated at 70C
for 10 min. For LXR variant expression, the protein lysate was loaded onto a 10% SDS polyacrylamide
gel, electrophoresed at constant 80 V for 150 min, and transferred onto a PVDF membrane (Merck, UK,
Cat. IPFL00010). The membrane was then blocked with TBS Odyssey Blocking Buffer (LI-COR Biosciences,
UK, Cat. 92750000) for 1 h. Proteins were probed with anti-LXRa (R&D Systems, USA, Cat. PP-PPZ0412-00,
dilution 1/1000), anti-LXRb (Active Motif, Germany, Cat. 61177, dilution 1/1000), and anti-HPRT (Santa Cruz
Biotechnology, Cat. sc-376938, dilution 1/100) overnight at 4C. The membrane was then blocked and
probed with LICOR secondary antibodies (IRDye 800CW goat anti-mouse Cat. 926-68170, IRDye 680RD
goat anti-rabbit Cat. 926-68071; dilution 1/15,000, LI-COR Biosciences, UK) for 1 h and signal was visualized
using the Odyssey system (LI-COR Biosciences, UK).
Immunoprecipitation
One mg protein sample was precleared with Dynabeads Protein A (Thermo Fisher, UK, Cat.100002D) and
1 mg isotype IgG2a (Cell Signalling, USA, Cat. 61656S). Immunoprecipitation was performed by incubating




Articlesuberate (Thermo Fisher, UK; Cat. A39266) with 1 mg protein sample overnight at 4C. Dynabeads were
washed 3 times with 10 mM Tris-HCl, 50 mM KCl (pH 7.5) and sample eluted in 20 mL of NUPAGE LDS sam-
ple loading buffer containing 100 mMDTT, then heated at 70C for 10 min 10 at 70C. The supernatant was
transferred to a new Eppendorf tube after being separated from Dynabeads using a magnetic separator
(Promega, UK, Cat. CD4002).In-silico peptide mass prediction
The amino acid sequences of LXR variants downloaded fromNCBI, ENSEMBL, and/or UNIPROT databases
were subjected to the PeptideMass tool (http://www.expasy.org/tools/peptide-mass.html; Swiss Institute
of Bioinformatics, Switzerland) (Gasteiger et al., 2003) to perform theoretical peptides from trypsin diges-
tion in silico. Trypsin is the most preferred protease choice for peptide generation due to its high proteo-
lytic activity and cleavage specificity (Saveliev et al., 2013). A set of peptides from each LXR variant were
then subjected to Diagram Venn (http://bioinformatics.psb.ugent.be/webtools/Venn; Bioinformatics &
Evolutionary Genomics, Belgium) in order to find the unique peptides of each LXR variant.S-trap column coupled mass spectrometry (MS)
Protein samples were processed using the S-TRAP Micro column (PROTIFI, NY, USA) following the manu-
facturer’s instructions. Proteins were fully solubilized by adding 20 mL of 10% SDS solution to 20 mL sample
in RIPA buffer. Reduction and alkylation were then performed. DTT was added to a final concentration of
20 mM before heating to 56C for 15 min with shaking. The sample was removed from heat and allowed to
cool for 5 min. Iodoacetamide was then added to a final concentration of 40 mM. The sample was main-
tained at 20C for 15 min with shaking in the dark. Phosphoric acid was then added to a final concentration
of 1.2%, to ensure inactivation of all enzymatic activity and maximize sensitivity to proteolysis. Samples
were then diluted with S-Trap binding buffer (100 mM TEAB pH 7.1 in methanol), and 1ug of trypsin, recon-
stituted in 50mM triethylamonium bicarbonate (TEAB), was added before the sample was quickly loaded
onto the S-trap column. Proteins were captured within the submicron pores of the three-dimensional trap.
Proteins captured within the trap present exceptionally high surface area allowing them to be washed free
of contaminants. The S-trap was washed by adding 150 mL binding buffer before being spun at 4000xg for
30 s. 30 mL of 0.02 mg/mL Trypsin (Promega, WI, USA) was then added to the top of the S-trap. S-traps were
loosely capped and placed in a 1.5mL Eppendorf and heated to 46C for 15 min with no shaking. Digested
peptides were eluted by first spinning the S-trap at 4,000 g for 1 min. Further elution was performed in 40 mL
50mM TEAB, 40 mL 0.2% formic acid, and 30 mL 50% acetonitrile with 0.2% formic acid prior to centrifuga-
tion. Eluent was combined then dried down prior to resuspension in 0.2% formic acid.QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analyses were performed using GraphPad Prism v8. The expression of LXR splice variants in
TCGA tumors compared with the adjacent normal tissues was assessed using a Mann-Whitney two-tailed
U test. Differential LXR splicing expression levels in both TCGA BCa and Leeds TNBC tumor samples were
established using multiple t-tests with Holm-Sidak for multiple correction. The knockdown siRNA experi-
ment was analyzed using a two-tailed one-way ANOVA. The relationship between protein isoform variants
and their mRNA transcripts were assessed using Spearman’s correlation and linear regression. Receiver
operating characteristic (ROC) curves were used to establish the expression cut offs for high and low
expression levels of each LXR variant. The true positive rate (the proportion of patients with the disease
correctly diagnosed) was plotted as a function of the false positive rate (proportion of patients without
the disease who are incorrectly diagnosed as having the disease) and the cut-off between ‘high’ and
‘low’ expression was determined by maximizing the clinical sensitivity (fraction of true positives to all pa-
tients with the disease correctly diagnosed) and specificity (fraction of true negatives to all patients without
the disease correctly diagnosed). Tumor expression of each LXR variant was then assessed alongside pa-
tient survival to assess whether expression is predictive of survival in Kaplan Meier graphs. Patient survival
was analyzed using log-rank test. Densitometry was performed using Image StudioTM Lite (LI-COR Biosci-
ences, UK) software.20 iScience 24, 103212, October 22, 2021
